A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Deferiprone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms SKY
- Sponsors ApoPharma
- 06 Apr 2018 Planned End Date changed from 1 Jul 2018 to 1 Oct 2019.
- 06 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 20 Jul 2016 Status changed from not yet recruiting to recruiting.